Annals of Internal Medicine 1982-05-01

Etidronate disodium in the treatment of Paget's disease of bone.

S M Krane

Index: Ann. Intern. Med. 96(5) , 619-25, (1982)

Full Text: HTML

Abstract

Control of Paget's disease of bone has been possible through treatment with agents that decrease bone resorption; calcitonins, diphosphonates, and mithramycin. The pagetic lesion is not, however, cured. Etidronate disodium is one of the diphosphonates. The clinical improvement attained with this drug has to be set against adverse effects, of which pain is probably the most bothersome in practice. Clinical remission can last as long as 2 years after treatment is stopped.

Related Compounds

  • Etidronate disodiu...

Related Articles:

Effects of various squalene epoxides on coenzyme Q and cholesterol synthesis.

2014-07-01

[Biochim. Biophys. Acta 1841(7) , 977-86, (2014)]

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

2014-12-01

[Lancet Oncol. 15(13) , 1460-8, (2014)]

A novel automated hydrophilic interaction liquid chromatography method using diode-array detector/electrospray ionization tandem mass spectrometry for analysis of sodium risedronate and related degradation products in pharmaceuticals

2014-10-24

[J. Chromatogr. A. 1365 , 131-9, (2014)]

Risk of atypical femoral fracture during and after bisphosphonate use.

2015-02-01

[Acta Orthop. 86(1) , 100-7, (2015)]

The role of risedronate in osteopenia in Crohn's disease.

2015-01-01

[Gut 64(1) , 185, (2015)]

More Articles...